Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
AVR
vs
S
S&P/ASX 300
AVR
Over the past 12 months, AVR has significantly outperformed S&P/ASX 300, delivering a return of +66% compared to S&P/ASX 300's 3% drop.
Stocks Performance
AVR vs S&P/ASX 300
Performance Gap
AVR vs S&P/ASX 300
Performance By Year
AVR vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anteris Technologies Ltd
Glance View
Anteris Technologies Ltd is a medical device company focused on heart valve replacement. It develops the DurAVR transcatheter aortic valve system, which is designed to replace a diseased aortic valve through a minimally invasive procedure instead of open-heart surgery. The company also works with specialized heart tissue technology that is used in its valve products. Its main customers are hospitals, heart doctors, and other healthcare providers that treat people with severe aortic valve disease. Anteris makes money by selling its valve systems and related device technology into the structural heart market, where treatment is usually chosen by physicians and paid for through the healthcare system. What makes Anteris different is that it is not a broad hospital equipment supplier. It is a focused developer of a single high-value treatment category: transcatheter heart valves. That puts it in a niche part of the medical device industry where product design, clinical performance, and physician trust matter more than large product breadth.
